- Evelo Biosciences (EVLO) -23% after provide clinical updates, data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint.
- Taysha Gene Therapies (TSHA) -18% as FDA seeks additional dosing for CNS disorder candidate.
- Snap SNAP -16% on Q4 earnings release.
- Hillstream BioPharma (HILS) -13%.
- Context Therapeutics (CNTX) -12%.
- G Medical Innovations (GMVD) -12%.
- SOBR Safe (SOBR) -10%.
- Electronic Arts (EA) -10% on Q3 earnings release.
- Match Group (MTCH) -9% on Q4 earnings release.
- Argo Blockchain (ARBK) -8% after finance chief steps back.
- Heart Test Laboratories (HSCS) -7%.
- Atlis Motor Vehicles (AMV) -6%.
- SHF Holdings (SHFS) -6%.
- Synchrony Financial (SYF) -5%.